Table 2 Anthropometric and analytic variables and treatment of the atherosclerotic patients groups

Anthropometric and analytical variables

 N

5

7

10

 Age (years)

59 ± 11

66 ± 14

61 ± 8

 Weight (Kg)

76.1 ± 13.7

71.8 ± 13.4

91.6 ± 24.8

 BMI (Kg/m²)

27.5 ± 3.8

26.3 ± 4.1

33 ± 3.4

 SBP (mm Hg)

131 ± 21

139 ± 18

121 ± 23

 DBP (mm Hg)

73 ± 15

81 ± 16

68 ± 9

 Glucose (mg/dL)

94 ± 5

97 ± 11

101 ± 11

 Total cholesterol (mg/dL)

153 ± 53

158 ± 38

138 ± 47

 LDL-C (mg/dL)

96 ± 40

106 ± 27

71 ± 30

 HDL-C (mg/dL)

32 ± 7

28 ± 10

41 ± 22

 Triglycerides (mg/dL)

119 (95–189)

135 (112–170)

122 (100–183)

 HbA1c (%)

5.3 ± 0.3

5.9 ± 0.2

6.5 ± 1.0

 Insulin (µU/mL)

14.2 ± 2.5

11.3 ± 6.0

13.2 ± 7.6

 HOMA index

3.3 ± 0.6

2.8 ± 1.7

3.3 ± 2.1

Cardiovascular risk factors

 Gender (% males)

80

57

80

 Arterial hypertension (%)

80

57

100

 Dyslipidemia (%)

80

57

60

 Smoking habits (%)

60

29

10

  Ex-smokers

40

14

20

  Non-smokers

0

57

70

 Obesity (%)

60

29

70

  Overweight

20

43

20

  Normal weight

20

28

10

Treatment N (%)

 Oral antidiabetics (ADO)

0 (0%)

0 (0%)

8 (80%)

  Metformin

0 (0%)

0 (0%)

7 (70%)

  Sulfonylureas

0 (0%)

0 (0%)

3 (30%)

 Insulin

0 (0%)

0 (0%)

4 (40%)

 Lipid-lowering drugs

2 (40%)

3 (42.9%)

8 (80%)

  Statins

2 (40%)

3 (42.9%)

8 (80%)

 Antihypertensives

4 (80%)

4 (57.1%)

10 (100%)

  ACE inhibitors

2 (40%)

1 (14.3%)

4 (40%)

  ARBs

0 (0%)

1 (14.3%)

5 (50%)

  Beta blockers

1 (20%)

3 (42.9%)

4 (40%)

 Antiaggregants

3 (60%)

5 (71.4%)

9 (90%)

  ASA

2 (40%)

4 (57.1%)

9 (90%)

  Clopidogrel

1 (20%)

1 (14.3%)

0 (0%)